Table 2.
Results of group-wise radiomic feature-based cancer classifications for hormone receptor status (training dataset)
| HR positive | HER2 positive | HR negative | HER2 negative | Her2-enriched | TN | All others | |
|---|---|---|---|---|---|---|---|
| HR positive | – | – |
67% (POE; 9) |
– | 79.4% (Fisher; 7) |
71.3% (Fisher; 8) |
67% (POE; 9) |
| HER2 positive | – | – | – |
73.6% (Fisher; 9) |
– |
59.5% (Fisher; 4) |
73.6% (Fisher; 9) |
| HR negative |
67% (POE; 9) |
– | – | – | – | – |
67% (POE; 9) |
| HER2 negative | – |
73.6% (Fisher; 9) |
– | – | – | – |
73.6% (Fisher; 9) |
| HER2-enriched |
79.4% (Fisher; 7) |
– | – | – | – | – | – |
| TN |
71.3% (Fisher; 8) |
59.5% (Fisher; 4) |
– | – | – | – | – |
| All others |
67% (POE; 9) |
73.6% (Fisher; 9) |
67% (POE; 9) |
73.6% (Fisher; 9) |
– | – | – |
HER2 human epidermal growth factor receptor 2, HR hormone receptor, MI mutual information, POE probability of error and average correlation, TN triple negative. The feature selection algorithm and number of features used for classification are given in parentheses